Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A1921 combination therapy in advanced solid tumors
CTR20230416Phase 2Active
- Sponsor
- Suzhou Shengdiya Biopharmaceuticals
- Start
- Apr 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of tizetatug rezetecan in Nonhematologic neoplasms, sponsored by Suzhou Shengdiya Biopharmaceuticals. Started Apr 2023; status: active.
02
Drugs
tizetatug rezetecan
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20230416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230416.